Lane Andrew H's Form 4 filing
Abbott Laboratories (ABT) · filed Aug 31, 2021
- Accession no.
- 0001415889-21-004154
- Filed
- Aug 31, 2021
- Trade date
- Aug 27, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $17.1M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lane Andrew HCIK 0001643735 | Officer (EXECUTIVE VICE PRESIDENT) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2021 | Common shares without par value | MOption exerciseAcquired | +135,925 | $38.40 | +$5,219,520 | 222,012 | Direct | |
| Aug 27, 2021 | Common shares without par value | SSaleDisposed | −135,925 | $125.48F2 | −$17,055,869 | 86,087 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2021 | Common Shares | MOption exerciseDisposed | −135,925 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.96 to $125.72, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).